



EAST Search History

| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|-------|------|-------------------------------|---|------------------|---------|------------------|
| L1 | 426 | (544/322).CCLS. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:09 |
| L2 | 540 | (544/324).CCLS. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:09 |
| L3 | 9 | cathlin.inv. and biwersi.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:10 |
| L4 | 58 | Dennis.inv. and McNamara.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:10 |
| L5 | 76 | Joseph.inv. and Repine.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:10 |
| L6 | 32 | Peter.inv. and Toogood.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:10 |
| L7 | 12 | Scott.inv. and Vanderwel.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:10 |
| L8 | 12 | Scott.inv. and Vanderwel.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:10 |

EAST Search History

| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|-------|------|-------------------------------|---|------------------|---------|------------------|
| L1 | 426 | (544/322).CCLS. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:09 |
| L2 | 540 | (544/324).CCLS. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:09 |
| L3 | 9 | cathlin.inv. and biwersi.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:10 |
| L4 | 58 | Dennis.inv. and McNamara.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:10 |
| L5 | 76 | Joseph.inv. and Repine.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:10 |
| L6 | 32 | Peter.inv. and Toogood.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:10 |
| L7 | 12 | Scott.inv. and Vanderwel.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:10 |
| L8 | 12 | Scott.inv. and Vanderwel.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2007/01/21 09:10 |



chain nodes :

7 15 16 17

ring nodes :

1 2 3 4 5 6 9 10 11 12 13 14

chain bonds :

4-7 5-17 7-9 13-15 14-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14

exact/norm bonds :

4-7 7-9 13-15

exact bonds :

5-17 14-16

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14



isolated ring systems :

containing 1 : 9 :

G1

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS16:CLASS17:CLASS



chain nodes :

7 8 21 28

ring nodes :

1 2 3 4 5 6 9 10 11 12 13 14 15 16 17 18 19 20 22 23 24 25 26 27

chain bonds :

4-7 7-8 14-21 20-22 26-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20 16-17 17-18
18-19 19-20 22-23 22-27 23-24 24-25 25-26 26-27

exact/norm bonds :

4-7 7-8 14-21 26-28

exact bonds :

20-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20 16-17 17-18
18-19 19-20 22-23 22-27 23-24 24-25 25-26 26-27

isolated ring systems :

containing 1 : 9 : 15 :

G1:[*1],[*2]

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:CLASS9:Atom 10:Atom 11:Atom 12:Atom
13:Atom

14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:CLAS22:Atom 23:Atom
24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS

10/759,749 ALW

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1226146 CAPLUS
DN 146:13164
TI Nitrogen-containing heterocyclic compounds as inhibitors of B-Raf kinase
IN Gahman, Timothy C.; Lang, Hengyuan; Davis, Robert L.; Scranton, Shawn A.
PA Kalypsys, Inc., USA
SO PCT Int. Appl., 114pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--|----------|-----------------|----------|
| PI | WO 2006124874 | A2 | 20061123 | WO 2006-US18885 | 20060511 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| PRAI | US 2005-680288P | P | 20050512 | | |
| | US 2005-680290P | P | 20050512 | | |
| | US 2005-680291P | P | 20050512 | | |
| | US 2005-680292P | P | 20050512 | | |
| | US 2005-680293P | P | 20050512 | | |
| | US 2005-680294P | P | 20050512 | | |
| | US 2005-680327P | P | 20050512 | | |
| IT | 915373-02-3 915373-04-5 | | | | |
| | RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (nitrogen-containing heterocyclic compds. as inhibitors of B-Raf kinase) | | | | |
| RN | 915373-02-3 CAPLUS | | | | |
| CN | 2,4-Pyrimidinediamine, N4-(3,4-dimethylphenyl)-N2-2-pyridinyl- (CA INDEX NAME) | | | | |



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 915373-04-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4-morpholinyl)phenyl]-N2-2-pyridinyl- (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 ALW

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:990201 CAPLUS
DN 146:7404
TI Theoretical study on stabilities of multiple hydrogen bonded dimers
AU Xu, Wei; Li, Xi-Chen; Tan, Hongwei; Chen, Guang-Ju
CS College of Chemistry, Beijing Normal University, Beijing, 100875, Peop.
Rep. China
SO Physical Chemistry Chemical Physics (2006), 8(38), 4427-4433
CODEN: PPCPFQ; ISSN: 1463-9076
PB Royal Society of Chemistry
DT Journal
LA English
IT 914772-76-2
RL: PRP (Properties)
(theor. study on stabilities of multiple hydrogen bonded dimers)
RN 914772-76-2 CAPLUS
CN 2,4-Pyrimidinediamine, N2-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:293263 CAPLUS

DN 144:350705

TI Substituted pyridine and pyrimidine compounds as pharmaceutical agents, their preparation, pharmaceutical compositions, and use in therapy

IN Andersen, Denise Lyn; Chang, Catherine H.; Falsey, James R.; Frohn, Michael J.; Hong, Fang-Tsao; Liao, Hongyu; Liu, Longbin; Lopez, Patricia; Retz, Daniel Martin; Rishton, Gilbert M.; Rzasa, Robert M.; Siegmund, Aaron; Tadesse, Seifu; Tamayo, Nuria; Tegley, Christopher M.

PA USA

SO U.S. Pat. Appl. Publ., 86 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | US 2006069110 | A1 | 20060330 | US 2005-237513 | 20050927 |
| | WO 2006037117 | A1 | 20060406 | WO 2005-US35134 | 20050927 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRAI US 2004-613762P P 20040927

OS MARPAT 144:350705



IT 881209-99-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted pyridine and pyrimidine compds. as anti-inflammatory, analgesic, or antidiabetic agents)

RN 881209-99-0 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[4-(1-cyclohexen-1-yl)-2-pyridinyl]-N4-methyl-N2-(2-phenylethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:194015 CAPLUS

DN 144:292768

TI Preparation of 2,4-di(aminophenyl)pyrimides as protein PLK1 inhibitors

IN Stadtmueller, Heinz; Engelhardt, Harald; Steegmaier, Martin; Baum, Anke; Guertler, Ulrich; Schoop, Andreas; Quant, Jens; Solca, Flavio; Hauptmann, Rudolf; Reiser, Ulrich; Zahn, Stephan Karl; Herfurth, Lars

PA Boehringer Ingelheim International G.m.b.H., Germany

SO PCT Int. Appl., 272 pp.


CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006021544 | A1 | 20060302 | WO 2005-EP54089 | 20050818 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | US 2006148800 | A1 | 20060706 | US 2005-206703 | 20050817 |
| PRAI | EP 2004-19775 | A | 20040820 | | |
| OS | MARPAT 144:292768 | | | | |
| IT | 878150-13-1P 878150-14-2P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 2,4-di(aminophenyl)pyrimides as protein PLK1 inhibitors) | | | | |
| RN | 878150-13-1 CAPLUS | | | | |
| CN | 1-Pyrrolidineacetamide, N-[6-[[4-[[2-(2-fluoroethyl)-2,3-dihydro-1-methyl-3-oxo-1H-isoindol-4-yl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME) | | | | |



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878150-14-2 CAPLUS

CN 1-Piperidineacetamide, 4-(dimethylamino)-N-[6-[[4-[[2-(2-fluoroethyl)-2,3-dihydro-1-methyl-3-oxo-1H-isoindol-4-yl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 878155-93-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2,4-di(aminophenyl)pyrimides as protein PLK1 inhibitors)

RN 878155-93-2 CAPLUS

CN Acetamide, 2-bromo-N-[6-[[4-[[2-(2-fluoroethyl)-2,3-dihydro-1-methyl-3-oxo-1H-isoindol-4-yl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:961232 CAPLUS
DN 143:253451
TI Hair coloring compositions containing phenylenediamine or diaminopyridine
couplers and diaminopyrazole intermediates
IN Lim, Mu'lll; Zhang, Guiru; Murphy, Bryan Patrick
PA USA
SO U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 90,377.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2005188480 | A1 | 20050901 | US 2005-77744 | 20050311 |
| | US 2003196280 | A1 | 20031023 | US 2002-90377 | 20020304 |
| | US 6887280 | B2 | 20050503 | | |
| | WO 2006099115 | A2 | 20060921 | WO 2006-US8559 | 20060310 |
| | WO 2006099115 | A3 | 20061221 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | US 2002-90377 | A2 | 20020304 | | |
| | US 2005-77744 | A | 20050311 | | |
| OS | MARPAT 143:253451 | | | | |
| IT | 863298-72-0 | | | | |
| | RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (hair coloring compns. containing phenylenediamine or diaminopyridine couplers and diaminopyrazole intermediates) | | | | |
| RN | 863298-72-0 CAPLUS | | | | |
| CN | Pyrimidinetetramine, N2-(6-amino-2-pyridinyl)- (9CI) (CA INDEX NAME) | | | | |



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 ALW

L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:517936 CAPLUS
DN 143:451473
TI Two novel copper(II) complexes with a novel ligand 2,4-Di(2-aminopyridine)-
6-methylpyrimidine
AU Ma, Hai-rui; Wang, Yao-yu; Liu, Ping; Li, Dong-sheng; Shi, Qi-zhen; Lee,
Gene-hsiang; Peng, Shie-ming
CS Department of Chemistry, Northwest University, Xian, 710069, Peop. Rep.
China
SO Chemical Research in Chinese Universities (2005), 21(3), 365-367
CODEN: CRCUED; ISSN: 1005-9040
PB Higher Education Press
DT Journal
LA English
OS CASREACT 143:451473
IT 848189-14-0
RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)
(crystal structure and reactant for preparation of copper complexes)
RN 848189-14-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N,N'-di-2-pyridinyl- (9CI) (CA INDEX
NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:158646 CAPLUS
DN 142:254587
TI Methods for treating or preventing autoimmune diseases with
2,4-pyrimidinediamine compounds
IN Rajinder, Singh; Ankush, Argade; Li, Hui; Bhamidipati, Somasekhar;
Carroll, David; Sylvain, Catherine; Clough, Jeffrey; Keim, Holger
PA Rigel Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 276 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 7

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|------------------|----------|
| PI | WO 2005016893 | A2 | 20050224 | WO 2004-US24716 | 20040730 |
| | WO 2005016893 | A3 | 20050609 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2004265288 | A1 | 20050224 | AU 2004-265288 | 20040730 |
| | CA 2533377 | A1 | 20050224 | CA 2004-2533377 | 20040730 |
| | US 2005209224 | A1 | 20050922 | US 2004-903870 | 20040730 |
| | US 7122542 | B2 | 20061017 | | |
| | US 2005234049 | A1 | 20051020 | US 2004-903263 | 20040730 |
| | EP 1656372 | A2 | 20060517 | EP 2004-786150 | 20040730 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR | | | |
| | BR 2004013018 | A | 20061003 | BR 2004-13018 | 20040730 |
| | CN 1849318 | A | 20061018 | CN 2004-80022235 | 20040730 |
| | JP 2007500722 | T | 20070118 | JP 2006-522105 | 20040730 |
| | NO 2006000992 | A | 20060228 | NO 2006-992 | 20060228 |
| PRAI | US 2003-491641P | P | 20030730 | | |
| | US 2003-531598P | P | 20031219 | | |
| | US 2004-572246P | P | 20040518 | | |
| | US 2004-572256P | P | 20040518 | | |
| | WO 2004-US24716 | W | 20040730 | | |
| OS | MARPAT 142:254587 | | | | |
| IT | 841294-23-3P | | | | |
| | RL: | PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | |
| | | (pyrimidinediamine compds. for treatment or prevention of autoimmune diseases) | | | |
| RN | 841294-23-3 CAPLUS | | | | |
| CN | 3-Pyridinecarboxylic acid, 2-[[4-[(3,4-dihydro-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME) | | | | |

10/759,749 ALW




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 ALW

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:120923 CAPLUS
DN 142:219300
TI 2,4-Pyrimidinediamines for use in the treatment or prevention of
autoimmune diseases
IN Rajinder, Singh; Ankush, Argade; Li, Hui; Bhamidipati, Somasekhar;
Carroll, David; Sylvain, Catherine; Clough, Jeffrey; Keim, Holger
PA Rigel Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 7

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|-----------------|----------|
| PI | WO 2005012294 | A1 | 20050210 | WO 2004-US24920 | 20040730 |
| | WO 2005012294 | A8 | 20051229 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 2005209224 | A1 | 20050922 | US 2004-903870 | 20040730 |
| | US 7122542 | B2 | 20061017 | | |
| | US 2005234049 | A1 | 20051020 | US 2004-903263 | 20040730 |
| PRAI | US 2003-491641P | P | 20030730 | | |
| | US 2003-531598P | P | 20031219 | | |
| | US 2004-572246P | P | 20040518 | | |
| | US 2004-572256P | P | 20040518 | | |
| OS | MARPAT 142:219300 | | | | |
| IT | 841294-23-3P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (pyrimidinediamines for use in the treatment or prevention of autoimmune diseases) | | | | |
| RN | 841294-23-3 CAPLUS | | | | |
| CN | 3-Pyridinecarboxylic acid, 2-[[4-[(3,4-dihydro-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME) | | | | |




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

10/759,749 ALW

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:61565 CAPLUS
DN 142:328292
TI Synthesis, characterization and crystal structures of 2,4-di(2-aminopyridine)-6-methylpyrimidine (dapmp), [Cu(dapmp)Cl₂] and [Cu(dapmp)(CH₃COO)₂]·H₂O
AU Ma, Hai-Rui; Wang, Yao-Yu; Liu, Ping; Li, Dong-Sheng; Shi, Qi-Zhen; Lee, Gene-Hsiang; Peng, Shie-Ming
CS Department of Chemistry, Shaanxi Key Laboratory of Physico-Inorganic Chemistiy, Northwest University, Xian, 710069, Peop. Rep. China
SO Polyhedron (2005), 24(2), 215-220
CODEN: PLYHDE; ISSN: 0277-5387
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 142:328292
IT 848189-14-0P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, crystal structure and complexation of bis(pyridinylamino)pyrimidine with copper(II))
RN 848189-14-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N,N'-di-2-pyridinyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:633921 CAPLUS
DN 141:174079
TI Preparation of 2-aminopyridines as cdk4 inhibitors
IN Biwersi, Cathlin Marie; Mcnamara, Dennis Joseph; Repine, Joseph Thomas;
Toogood, Peter Laurence; Vanderwel, Scott Norman; Warmus, Joseph Scott
PA Warner-Lambert Company Llc, USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004065378 | A1 | 20040805 | WO 2004-IB91 | 20040109 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ | | | | |
| | CA 2512646 | A1 | 20040805 | CA 2004-2512646 | 20040109 |
| | EP 1590341 | A1 | 20051102 | EP 2004-701058 | 20040109 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2004006809 | A | 20051227 | BR 2004-6809 | 20040109 |
| | JP 2006516561 | T | 20060706 | JP 2006-500296 | 20040109 |
| | US 2004236084 | A1 | 20041125 | US 2004-759749 | 20040116 |
| PRAI | US 2003-440805P | P | 20030117 | | |
| | WO 2004-IB91 | W | 20040109 | | |
| OS | MARPAT 141:174079 | | | | |
| IT | 733038-85-2P, 4-[6-[[5-Amino-4-(cyclopentylamino)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester | | | | |
| | RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) | | | | |
| | (cdk4 inhibitor; preparation of 2-aminopyridines as cdk4 inhibitors for treating cell proliferative disorders) | | | | |
| RN | 733038-85-2 CAPLUS | | | | |
| CN | 1-Piperazinecarboxylic acid, 4-[6-[[5-amino-4-(cyclopentylamino)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME) | | | | |



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 733038-77-2P, 4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid ethyl ester hydrochloride
733038-80-7P, 4-[6-[[5-Bromo-4-(cyclopentylamino)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester
733038-83-0P, 4-[6-(5-Acetyl-4-aminopyrimidin-2-ylamino)pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 733038-84-1P
733039-16-2P, 4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carbonitrile 733039-19-5P,
5-Bromo-N'-cyclopentyl-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-29-7P, N'-Cyclopentyl-5-nitro-N-[5-(piperazin-1-


yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-30-0P,
 4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-
 carboxaldehyde 733039-31-1P, 4-Cyclopentylamino-2-[5-(piperazin-
 1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid ethyl ester
 733039-32-2P, 4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-
 ylamino]pyrimidine-5-carboxylic acid methyl ester 733039-33-3P,
 [4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-
 yl]methanol 733039-34-4P, 1-[4-Cyclopentylamino-2-[5-(piperazin-
 1-yl)pyridin-2-ylamino]pyrimidin-5-yl]ethanone 733039-35-5P,
 3-[4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-
 yl]but-2-enoic acid ethyl ester 733039-36-6P,
 4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carbonitrile
 733039-37-7P, 5-Nitro-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-
 2,4-diamine 733039-38-8P, 4-Amino-2-[5-(piperazin-1-yl)pyridin-2-
 ylamino]pyrimidine-5-carboxaldehyde 733039-39-9P,
 4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic
 acid ethyl ester 733039-40-2P, 4-Amino-2-[5-(piperazin-1-
 yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid methyl ester
 733039-41-3P, [4-Amino-2-[5-(piperazin-1-yl)pyridin-2-
 ylamino]pyrimidin-5-yl]methanol 733039-42-4P,
 1-[4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]ethanone
 733039-43-5P, 3-[4-Amino-2-[5-(piperazin-1-yl)pyridin-2-
 ylamino]pyrimidin-5-yl]but-2-enoic acid ethyl ester 733039-44-6P
 , 4-Cyclopentylamino-2-[5-(pyrrolidin-1-yl)pyridin-2-ylamino]pyrimidine-5-
 carbonitrile 733039-45-7P, N-[5-(3-Aminopyrrolidin-1-yl)pyridin-
 2-yl]-N'-cyclopentyl-5-nitropyrimidine-2,4-diamine 733039-46-8P,
 4-Cyclopentylamino-2-[5-(morpholin-4-yl)pyridin-2-ylamino]pyrimidine-5-
 carboxaldehyde 733039-47-9P, 4-Cyclopentylamino-2-[(3,4,5,6-
 tetrahydro-2H-[1,3']bipyridinyl-6'-yl)amino]pyrimidine-5-carboxylic acid
 ethyl ester 733039-48-0P, 4-Cyclopentylamino-6-methyl-2-[5-
 (piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid methyl
 ester 733039-49-1P, [2-[5-[Bis(methoxymethyl)amino]pyridin-2-
 yl]amino]-4-(cyclopentylamino)pyrimidin-5-yl]methanol 733039-50-4P
 , 1-[4-Benzylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-
 yl]ethanone 733039-51-5P, 4-[4-Cyclopentylamino-2-[5-(piperazin-
 1-yl)pyridin-2-ylamino]pyrimidin-5-yl]pent-3-en-2-one 733039-52-6P
 , 4-Amino-2-(pyridin-2-ylamino)pyrimidine-5-carbonitrile
 733039-53-7P, 5-Nitro-N-pyridin-2-ylpyrimidine-2,4-diamine
 733039-54-8P, 4-Amino-2-(pyridin-2-ylamino)pyrimidine-5-
 carboxaldehyde 733039-55-9P, 4-Amino-2-(pyridin-2-
 ylamino)pyrimidine-5-carboxylic acid ethyl ester 733039-56-0P,
 5-Bromo-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine
 733039-57-1P, [4-Amino-2-[5-(morpholin-4-yl)pyridin-2-
 ylamino]pyrimidin-5-yl]methanol 733039-58-2P,
 1-[4-Amino-2-[5-(morpholin-4-yl)pyridin-2-ylamino]pyrimidin-5-yl]ethanone
 733039-59-3P, [[6-(5-Acetyl-4-aminopyrimidin-2-ylamino)pyridin-3-
 yl]oxy]acetic acid 733039-60-6P, 4-Cyclopentylamino-2-[4-
 hydroxymethyl-5-(pyrrolidin-1-yl)pyridin-2-ylamino]pyrimidine-5-
 carbonitrile 733039-61-7P, N-[5-(3-Aminopyrrolidin-1-yl)-6-
 chloropyridin-2-yl]-N'-cyclopentyl-5-nitropyrimidine-2,4-diamine
 733039-62-8P, 2-(5-Bromopyridin-2-ylamino)-4-
 (cyclopentylamino)pyrimidine-5-carboxaldehyde 733039-64-0P,
 4-Cyclopentylamino-2-[4,6-dichloro-5-(piperazin-1-yl)pyridin-2-ylamino]-6-
 methylpyrimidine-5-carboxylic acid methyl ester 733039-65-1P,
 2-[2-[5-[Bis(2-methoxyethyl)amino]pyridin-2-yl]amino]-4-
 (cyclopentylamino)pyrimidin-5-yl]-2-methylpropan-1-ol 733039-66-2P
 , 1-[4-Phenylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-
 yl]ethanone 733039-67-3P, 4-[4-(3-Hydroxycyclopentylamino)-2-[5-
 (piperazin-1-yl)pyridin-2-yl]amino]pyrimidin-5-yl]pent-3-en-2-one
 733039-68-4P, 4-[5-Cyano-2-(pyridin-2-ylamino)pyrimidin-4-
 yl]amino]cyclohexanecarboxylic acid 733039-69-5P,

2-(4-Amino-5-nitropyrimidin-2-ylamino)isonicotinic acid
 733039-70-8P, 4-Amino-6-methyl-2-(pyridin-2-ylamino)pyrimidine-5-carboxaldehyde 733039-71-9P, 5-Iodo-N-pyridin-2-ylpyrimidine-2,4-diamine 733039-72-0P, N-[5-Bromo-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-4-yl]acrylamide 733039-73-1P, N-[5-(Piperazin-1-yl)pyridin-2-yl]-5-prop-1-ynylpyrimidine-2,4-diamine 733039-74-2P, 5-[2-(4-Fluorophenyl)ethyl]-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-75-3P, [[6-(4-Amino-5-allylpyrimidin-2-ylamino)pyridin-3-yl]oxy]acetic acid 733039-76-4P, 5-Bromo-N'-cyclopentyl-N-[5-(pyrrolidin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-77-5P, N-[5-(3-Aminopyrrolidin-1-yl)-6-chloropyridin-2-yl]-5-bromo-N'-cyclopentylpyrimidine-2,4-diamine 733039-79-7P, 5-Bromo-N'-cyclopentyl-N-[4,6-dichloro-5-(piperazin-1-yl)pyridin-2-yl]-6-methylpyrimidine-2,4-diamine 733039-80-0P, N-[5-[Bis(2-methoxyethyl)amino]pyridin-2-yl]-5-bromo-N'-cyclopentylpyrimidine-2,4-diamine 733039-81-1P, 5-Bromo-N'-phenyl-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-82-2P, 3-[[5-Bromo-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-4-yl]amino]cyclopentanol 733039-83-3P, N'-Cyclopentyl-5-iodo-N-[5-(pyrrolidin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-84-4P, N-[5-(3-Aminopyrrolidin-1-yl)-6-chloropyridin-2-yl]-N'-cyclopentyl-5-iodopyrimidine-2,4-diamine 733039-85-5P, N'-Cyclopentyl-5-iodo-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-87-7P, 4-[6-(4-Cyclopentylamino-5-formylpyrimidin-2-ylamino)pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 733039-88-8P, 4-[6-[[5-Acetyl-4-(cyclopentylamino)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 733039-93-5P, 4-[6-[[4-Cyclopentylamino-5-(1-methyl-3-oxobut-1-enyl)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 733040-28-3P, 5-Fluoro-N'-isopropyl-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(cdk4 inhibitor; preparation of 2-aminopyridines as cdk4 inhibitors for treating cell proliferative disorders)

RN 733038-77-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




Ox HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733038-80-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[5-bromo-4-(cyclopentylamino)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733038-83-0 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[(5-acetyl-4-amino-2-pyrimidinyl)amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733038-84-1 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[4-(cyclopentylamino)-5-nitro-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-16-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-19-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-cyclopentyl-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-29-7 CAPLUS


CN 2,4-Pyrimidinediamine, N4-cyclopentyl-5-nitro-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-30-0 CAPLUS


CN 5-Pyrimidinecarboxaldehyde, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-31-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-32-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-33-3 CAPLUS


CN 5-Pyrimidinemethanol, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-34-4 CAPLUS


CN Ethanone, 1-[4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-35-5 CAPLUS

CN 2-Butenoic acid, 3-[4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-36-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-37-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-nitro-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-38-8 CAPLUS


CN 5-Pyrimidinecarboxaldehyde, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-39-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-40-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-41-3 CAPLUS


CN 5-Pyrimidinemethanol, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-42-4 CAPLUS


CN Ethanone, 1-[4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-
pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-43-5 CAPLUS

CN 2-Butenoic acid, 3-[4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-
pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-44-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[[5-(1-pyrrolidinyl)-2-
pyridinyl]amino]- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-45-7 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[5-(3-amino-1-pyrrolidinyl)-2-pyridinyl]-N4-cyclopentyl-5-nitro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-46-8 CAPLUS


CN 5-Pyrimidinecarboxaldehyde, 4-(cyclopentylamino)-2-[[5-(4-morpholinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-47-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-(1-piperidiny)-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-48-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-6-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-49-1 CAPLUS


CN 5-Pyrimidinemethanol, 2-[[5-[bis(methoxymethyl)amino]-2-pyridinyl]amino]-4-(cyclopentylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-50-4 CAPLUS


CN Ethanone, 1-[4-[(phenylmethyl)amino]-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-51-5 CAPLUS

CN 3-Penten-2-one, 4-[4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-52-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-amino-2-(2-pyridinylamino)- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-53-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-nitro-N2-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-54-8 CAPLUS


CN 5-Pyrimidinecarboxaldehyde, 4-amino-2-(2-pyridinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-55-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-amino-2-(2-pyridinylamino)-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-56-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-57-1 CAPLUS

10/759,749 ALW


CN 5-Pyrimidinemethanol, 4-amino-2-[[5-(4-morpholinyl)-2-pyridinyl]amino]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-58-2 CAPLUS


CN Ethanone, 1-[4-amino-2-[[5-(4-morpholinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-59-3 CAPLUS


CN Acetic acid, [[6-[(5-acetyl-4-amino-2-pyrimidinyl)amino]-3-pyridinyl]oxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-60-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[[4-(hydroxymethyl)-5-(1-pyrrolidinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-61-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[5-(3-amino-1-pyrrolidinyl)-6-chloro-2-pyridinyl]-N4-cyclopentyl-5-nitro- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-62-8 CAPLUS


CN 5-Pyrimidinecarboxaldehyde, 2-[(5-bromo-2-pyridinyl)amino]-4-(cyclopentylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-64-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[4,6-dichloro-5-(1-piperazinyl)-2-pyridinyl]amino]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-65-1 CAPLUS

CN 5-Pyrimidineethanol, 2-[[5-[bis(2-methoxyethyl)amino]-2-pyridinyl]amino]-4-(cyclopentylamino)-β,β-dimethyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-66-2 CAPLUS

CN Ethanone, 1-[4-(phenylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-67-3 CAPLUS


CN 3-Penten-2-one, 4-[4-[(3-hydroxycyclopentyl)amino]-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-68-4 CAPLUS


CN Cyclohexanecarboxylic acid, 4-[[5-cyano-2-(2-pyridinylamino)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-69-5 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[(4-amino-5-nitro-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-70-8 CAPLUS

CN 5-Pyrimidinecarboxaldehyde, 4-amino-6-methyl-2-(2-pyridinylamino)- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-71-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-iodo-N2-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-72-0 CAPLUS


CN 2-Propenamide, N-[5-bromo-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-73-1 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[5-(1-piperazinyl)-2-pyridinyl]-5-(1-propynyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-74-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-[2-(4-fluorophenyl)ethyl]-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-75-3 CAPLUS


CN Acetic acid, [[6-[[4-amino-5-(2-propenyl)-2-pyrimidinyl]amino]-3-pyridinyl]oxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-76-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-cyclopentyl-N2-[5-(1-pyrrolidinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-77-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[5-(3-amino-1-pyrrolidinyl)-6-chloro-2-pyridinyl]-5-bromo-N4-cyclopentyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-79-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-cyclopentyl-N2-[4,6-dichloro-5-(1-piperazinyl)-2-pyridinyl]-6-methyl- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-80-0 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[5-[bis(2-methoxyethyl)amino]-2-pyridinyl]-5-bromo-N4-cyclopentyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-81-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-phenyl-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-82-2 CAPLUS

CN Cyclopentanol, 3-[[5-bromo-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-83-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-cyclopentyl-5-iodo-N2-[5-(1-pyrrolidinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-84-4 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[5-(3-amino-1-pyrrolidinyl)-6-chloro-2-pyridinyl]-N4-cyclopentyl-5-iodo- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-85-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-cyclopentyl-5-iodo-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-87-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[6-[[4-(cyclopentylamino)-5-formyl-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-88-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[6-[[5-acetyl-4-(cyclopentylamino)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-93-5 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[4-(cyclopentylamino)-5-(1-methyl-3-oxo-1-butenyl)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733040-28-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N4-(1-methylethyl)-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 733039-18-4P, 4-[6-[[5-Cyano-4-(cyclopentylamino)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 2-aminopyridines as cdk4 inhibitors for treating cell proliferative disorders)

RN 733039-18-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[6-[[5-cyano-4-(cyclopentylamino)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




10/759,749 ALW

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 733038-79-4, 2-[[5-(4-tert-Butoxycarbonylpiperazin-1-yl)pyridin-2-yl]amino]-4-(cyclopentylamino)pyrimidine-5-carboxylic acid ethyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-aminopyridines as cdk4 inhibitors for treating cell proliferative disorders)

RN 733038-79-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]-2-pyridinyl]amino]-, ethyl ester
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:236703 CAPLUS
DN 140:423636
TI Solid-Phase Synthesis of 2,4-Diaminopyrimidines via Lewis Acid-Mediated
Aromatic Nucleophilic Substitution
AU Arvanitis, Elena A.; Chadha, Naresh; Pottorf, Richard S.; Player, Mark R.
CS 3-Dimensional Pharmaceuticals Inc., Cranbury, NJ, 08512, USA
SO Journal of Combinatorial Chemistry (2004), 6(3), 414-419
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
OS CASREACT 140:423636
IT 691402-43-4P 691402-45-6P 691402-61-6P
691402-63-8P 691402-79-6P 691402-81-0P
691402-97-8P 691402-99-0P 691403-15-3P
691403-17-5P 691403-34-6P 691403-36-8P
691403-59-5P 691403-62-0P 691403-86-8P
691403-89-1P 691404-13-4P 691404-16-7P
691404-39-4P 691404-62-3P 691404-65-6P
691404-87-2P 691404-89-4P 691405-08-0P
691405-10-4P 691405-26-2P 691405-28-4P
691405-45-5P 691405-48-8P 691405-64-8P
691405-66-0P 691405-82-0P 691405-84-2P
691406-00-5P 691406-02-7P 691406-08-3P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP
(Preparation)
(solid-phase combinatorial synthesis of 2,4-diaminopyrimidines via
Lewis acid-mediated aromatic nucleophilic substitution)
RN 691402-43-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(5-methyl-2-pyridinyl)-N4-(phenylmethyl)-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691402-42-3
CMF C17 H17 N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



10/759,749 ALW


RN 691402-45-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[3-(phenylmethoxy)-2-pyridinyl]-N4-(phenylmethyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-44-5

CMF C23 H21 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691402-61-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(5-methyl-2-pyridinyl)-N4-[(tetrahydro-2-furanyl)methyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-60-5

CMF C15 H19 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/759,749 ALW




RN 691402-63-8 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[3-(phenylmethoxy)-2-pyridinyl]-N4-[(tetrahydro-2-furanyl)methyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-62-7

CMF C21 H23 N5 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691402-79-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(4-methylphenyl)methyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-78-5

CMF C18 H19 N5




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 ALW

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691402-81-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(4-methylphenyl)methyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-80-9

CMF C24 H23 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691402-97-8 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[3-(1-methylethoxy)propyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-96-7

CMF C16 H23 N5 O

10/759,749 ALW




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691402-99-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[3-(1-methylethoxy)propyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-98-9

CMF C22 H27 N5 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-15-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(2,4-dichlorophenyl)ethyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

10/759,749 ALW


CRN 691403-14-2
CMF C18 H17 Cl2 N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691403-17-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[2-(2,4-dichlorophenyl)ethyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-16-4
CMF C24 H21 Cl2 N5 O




10/759,749 ALW

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-34-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(3,4-dimethoxyphenyl)ethyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-33-5

CMF C20 H23 N5 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-36-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(3,4-dimethoxyphenyl)ethyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

10/759,749 ALW


CRN 691403-35-7
CMF C26 H27 N5 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691403-59-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[(2-methoxyphenyl)methyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-58-4
CMF C18 H19 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2

10/759,749 ALW




RN 691403-62-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(2-methoxyphenyl)methyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-61-9

CMF C24 H23 N5 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-86-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(4-fluorophenyl)methyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-85-7


CMF C17 H16 F N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


CM 2 .

CMF C2 H F3 O2




CN 2,4-Pyrimidinediamine, N4-[(4-fluorophenyl)methyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CMFC23H20FN5O

CM 2


CMF C2 H F3 O2



CN 2,4-Pyrimidinediamine, N2-(5-methyl-2-pyridinyl)-N4-propyl-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CMF C13 H17 N5




10/759,749 ALW

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-16-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[3-(phenylmethoxy)-2-pyridinyl]-N4-propyl-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-15-6

CMF C19 H21 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691404-39-4 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-4-
[(phenylmethyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-38-3

CMF C24 H20 N6 O

10/759,749 ALW




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-62-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(5-methyl-2-pyridinyl)amino]-4-[[(tetrahydro-2-furanyl)methyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-61-2

CMF C16 H18 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-65-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-4-[[(tetrahydro-2-furanyl)methyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

10/759,749 ALW

CM 1


CRN 691404-64-5
CMF C22 H22 N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691404-87-2 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[[[(4-methylphenyl)methyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-86-1
CMF C19 H18 N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2


10/759,749 ALW



RN 691404-89-4 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[[[4-methylphenyl)methyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691404-88-3
CMF C25 H22 N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691405-08-0 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[[3-(1-methylethoxy)propyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-07-9
CMF C17 H22 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 ALW

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-10-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[3-(1-methylethoxy)propyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-09-1

CMF C23 H26 N6 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691405-26-2 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-25-1

CMF C19 H16 Cl2 N6

10/759,749 ALW




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-28-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-27-3

CMF C25 H20 Cl2 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

10/759,749 ALW


CRN 76-05-1
CMF C2 H F3 O2



RN 691405-45-5 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691405-44-4
CMF C21 H22 N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 691405-48-8 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-47-7
CMF C27 H26 N6 O3

10/759,749 ALW




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-64-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[(2-methoxyphenyl)methyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-63-7

CMF C19 H18 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

10/759,749 ALW


CRN 76-05-1
CMF C2 H F3 O2



RN 691405-66-0 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[[[(2-methoxyphenyl)methyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691405-65-9
CMF C25 H22 N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 691405-82-0 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[[[(4-fluorophenyl)methyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-81-9
CMF C18 H15 F N6

10/759,749 ALW




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-84-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[(4-fluorophenyl)methyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-83-1

CMF C24 H19 F N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/759,749 ALW




RN 691406-00-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(5-methyl-2-pyridinyl)amino]-4-(propylamino)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-99-9

CMF C14 H16 N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691406-02-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-4-(propylamino)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691406-01-6

CMF C20 H20 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

10/759,749 ALW


CRN 76-05-1
CMF C2 H F3 O2



RN 691406-08-3 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-[(5-methyl-2-pyridinyl)amino]-4-
[(phenylmethyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691406-07-2
CMF C18 H16 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:107925 CAPLUS
DN 140:303243
TI Two-photon absorption properties of star-shaped compounds based on
1,3,5-triazine and 1,3,5-trisubstituted benzene
AU Zhou, Xin; Ren, Ai-Min; Feng, Ji-Kang; Liu, Xiao-Juan
CS Institute of Theoretical Chemistry, State Key Laboratory of Theoretical
and Computational Chemistry, Jilin University, Changchun, 130023, Peop.
Rep. China
SO THEOCHEM (2004), 668(2-3), 229-234
CODEN: THEODJ; ISSN: 0166-1280
PB Elsevier Science B.V.
DT Journal
LA English
IT 676520-46-0
RL: PRP (Properties)
(two-photon absorption properties of star-shaped compds. based on
1,3,5-triazine and 1,3,5-trisubstituted benzene)
RN 676520-46-0 CAPLUS
CN 2,4,6-Pyrimidinetriamine, N,N,N',N',N'',N''-hexa-2-pyridinyl- (9CI) (CA
INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:356443 CAPLUS

DN 138:368916

TI Preparation of heteroarylamines as glycogen synthase kinase 3beta inhibitors

IN Freyne, Eddy Jean Edgard; Buijnsters, Peter Jacobus Johannes Antonius; Willems, Marc; Embrechts, Werner Constant Johan; Love, Christopher John; Janssen, Paul Adriaan Jan; Lewi, Paulus Joannes; Heeres, Jan; De Jonge, Marc Rene; Koymans, Lucien Maria Henricus; Vinkers, Hendrik Maarten; Van Aken Koen, Jeanne Alfons; Diels, Gaston Stanislas Marcella

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2003037891 | A1 | 20030508 | WO 2002-EP12077 | 20021029 |
| | WO 2003037891 | A8 | 20030904 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2463822 | A1 | 20030508 | CA 2002-2463822 | 20021029 |
| | EP 1448556 | A1 | 20040825 | EP 2002-790307 | 20021029 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | |
| | BR 2002013792 | A | 20041207 | BR 2002-13792 | 20021029 |
| | CN 1582285 | A | 20050216 | CN 2002-821900 | 20021029 |
| | HU 200402106 | A2 | 20050228 | HU 2004-2106 | 20021029 |
| | JP 2005507423 | T | 20050317 | JP 2003-540172 | 20021029 |
| | NZ 531853 | A | 20060224 | NZ 2002-531853 | 20021029 |
| | US 2005004125 | A1 | 20050106 | US 2004-493452 | 20040423 |
| | NO 2004001911 | A | 20040510 | NO 2004-1911 | 20040510 |
| PRAI | EP 2001-204196 | A | 20011101 | | |
| | WO 2002-EP12077 | W | 20021029 | | |

OS MARPAT 138:368916

IT 521951-07-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroarylamines as glycogen synthase kinase 3β (GSK3β) inhibitors for preventing or treating GSK3β-mediated diseases)

RN 521951-07-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(5-bromo-2-pyridinyl)-N4-(2,4,6-trimethylphenyl)-(9CI) (CA INDEX NAME)

10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1956:56933 CAPLUS

DN 50:56933

OREF 50:10729d-i,10730a-h

TI Quaternary salts from 2-chloro-5-nitropyrimidines. I. Preparation and some reactions

AU Spickett, R. G. W.; Timmis, G. M.

CS Roy. Cancer Hosp., London

SO Journal of the Chemical Society (1955) 4354-9

CODEN: JCSOA9; ISSN: 0368-1769


DT Journal

LA Unavailable

IT 733039-53-7P, Pyrimidine, 4-amino-5-nitro-2-(2-pyridylamino)-
857428-16-1P, Pyrimidine, 4-methyl-2,6-bis(6-methyl-2-
pyridylamino)-5-nitro- 874494-56-1P, Pyrimidine,
2,4-bis(6-methyl-2-pyridylamino)-5-nitro-
RL: PREP (Preparation)
(preparation of)

RN 733039-53-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-nitro-N2-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 857428-16-1 CAPLUS

CN Pyrimidine, 4-methyl-2,6-bis(6-methyl-2-pyridylamino)-5-nitro- (5CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 874494-56-1 CAPLUS

CN Pyrimidine, 2,4-bis(6-methyl-2-pyridylamino)-5-nitro- (5CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


10/759,749 ALW

L4 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1952:48660 CAPLUS
DN 46:48660
OREF 46:8121g-i,8122a-c
TI Quaternary salts from 2-chloro-5-nitropyrimidines, and their reactions
AU Spickett, R. G. W.; Timmis, G. M.
CS Roy. Cancer Hosp., London
SO Chemistry & Industry (London, United Kingdom) (1951) 937-9
CODEN: CHINAG; ISSN: 0009-3068
DT Journal
LA Unavailable
IT 859208-12-1P, Pyrimidine, 4-anilino-5-nitro-2-(2-pyridylamino)-
874494-56-1P, Pyrimidine, 2,4-bis(6-methyl-2-pyridylamino)-5-nitro-
RL: PREP (Preparation)
(preparation of)
RN 859208-12-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 874494-56-1 CAPLUS
CN Pyrimidine, 2,4-bis(6-methyl-2-pyridylamino)-5-nitro- (5CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


10/759,749 ALW

L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1948:32077 CAPLUS
DN 42:32077
OREF 42:6830e-i,6831a
TI Synthetic antimalarials. XXVI. Pyridyl- and pyrimidylaminopyrimidines
AU Curd, F. H. S.; Graham, W.; Rose, F. L.
CS Imp. Chem. Industries Ltd., Blackley, UK
SO Journal of the Chemical Society (1948) 594-7
CODEN: JCSOA9; ISSN: 0368-1769
DT Journal
LA Unavailable
IT 856851-88-2P, Pyrimidine, 4-(2-diethylaminoethylamino)-6-methyl-2-(2-pyridylamino)-, dihydrochloride 856855-34-0P, Pyrimidine, 4-methyl-6-p-nitroanilino-2-(2-pyridylamino)-, dihydrochloride 856976-15-3P, Pyrimidine, 4-p-chloroanilino-6-methyl-2-(2-pyridylamino)-, dihydrochloride
RL: PREP (Preparation)
(preparation of)
RN 856851-88-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



●2 HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 856855-34-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



●2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 856976-15-3 CAPLUS
CN Pyrimidine, 4-p-chloroanilino-6-methyl-2-(2-pyridylamino)-, dihydrochloride (5CI) (CA INDEX NAME)

10/759,749 ALW



●2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|--------------|--|--------|--|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | OCT 23 | The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded |
| NEWS | 4 | OCT 30 | CHEMLIST enhanced with new search and display field |
| NEWS | 5 | NOV 03 | JAPIO enhanced with IPC 8 features and functionality |
| NEWS | 6 | NOV 10 | CA/CAPLUS F-Term thesaurus enhanced |
| NEWS | 7 | NOV 10 | STN Express with Discover! free maintenance release Version 8.01c now available |
| NEWS | 8 | NOV 20 | CAS Registry Number crossover limit increased to 300,000 in additional databases |
| NEWS | 9 | NOV 20 | CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000 |
| NEWS | 10 | DEC 01 | CAS REGISTRY updated with new ambiguity codes |
| NEWS | 11 | DEC 11 | CAS REGISTRY chemical nomenclature enhanced |
| NEWS | 12 | DEC 14 | WPIDS/WPINDEX/WPIX manual codes updated |
| NEWS | 13 | DEC 14 | GBFULL and FRFULL enhanced with IPC 8 features and functionality |
| NEWS | 14 | DEC 18 | CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role |
| NEWS | 15 | DEC 18 | CA/CAPLUS patent kind codes updated |
| NEWS | 16 | DEC 18 | MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000 |
| NEWS | 17 | DEC 18 | MEDLINE updated in preparation for 2007 reload |
| NEWS | 18 | DEC 27 | CA/CAPLUS enhanced with more pre-1907 records |
| NEWS | 19 | JAN 08 | CHEMLIST enhanced with New Zealand Inventory of Chemicals |
| NEWS | 20 | JAN 16 | CA/CAPLUS Company Name Thesaurus enhanced and reloaded |
| NEWS | 21 | JAN 16 | IPC version 2007.01 thesaurus available on STN |
| NEWS | 22 | JAN 16 | WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data |
| | | | |
| NEWS EXPRESS | NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006. | | |
| | | | |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability | | |
| NEWS LOGIN | Welcome Banner and News Items | | |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 | | |
| NEWS X25 | X.25 communication option no longer available | | |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

10/759,749 2

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:23:55 ON 21 JAN 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 08:24:04 ON 21 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JAN 2007 HIGHEST RN 917943-10-3

DICTIONARY FILE UPDATES: 19 JAN 2007 HIGHEST RN 917943-10-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\107597492.str



chain nodes :

7 8 21 28

ring nodes :

1 2 3 4 5 6 9 10 11 12 13 14 15 16 17 18 19 20 22 23 24 25 26
27

chain bonds :

4-7 7-8 14-21 20-22 26-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20
16-17 17-18 18-19 19-20 22-23 22-27 23-24 24-25 25-26 26-27

exact/norm bonds :

4-7 7-8 14-21 26-28

exact bonds :

20-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20
16-17 17-18 18-19 19-20 22-23 22-27 23-24 24-25 25-26 26-27

isolated ring systems :

containing 1 : 9 : 15 :

G1:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS

10/759,749 2

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 08:24:26 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 203 TO ITERATE

100.0% PROCESSED 203 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 3206 TO 4914


PROJECTED ANSWERS: 2442 TO 3958

L2 50 SEA SSS SAM L1

=> d scan

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H18 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):49

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H17 N7 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C15 H18 Br N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H12 Cl F3 N6 O4



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H16 N8 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C15 H10 Cl2 N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C17 H17 Cl N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H17 N7 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C15 H15 N7 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C13 H15 Br N6 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,6-Pyrimidinediamine, 5-nitro-N-(phenylmethyl)-N-2-pyridinyl-N'-[4-(trifluoromethyl)phenyl]- (9CI)
MF C23 H17 F3 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C16 H13 Br N6 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C15 H11 Cl N8 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C17 H9 Cl F6 N6 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H20 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C16 H22 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C13 H17 Cl N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 4,6-Pyrimidinediamine, N'-(3,4-difluorophenyl)-5-nitro-N-(phenylmethyl)-N-
2-pyridinyl- (9CI)


MF C22 H16 F2 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C16 H12 Br N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C15 H9 Cl2 F N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C16 H14 N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C13 H18 N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C19 H16 Cl F3 N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C11 H14 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C22 H15 Cl F3 N7 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C16 H11 Br F N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H18 N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C17 H15 N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C22 H18 Br F N6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C14 H20 N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H24 N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 4,6-Pyrimidinediamine, N'-(2-methoxyphenyl)-5-nitro-N-(phenylmethyl)-N-2-
pyridinyl- (9CI)


MF C23 H20 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C16 H11 Br N8 O5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE.

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C24 H24 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C16 H12 F N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C16 H11 Br Cl F3 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H20 N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C13 H18 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C13 H12 Cl N7 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C16 H11 Br Cl N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C16 H12 Cl2 N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H20 N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C19 H17 N7



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C23 H22 N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C19 H17 N7



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C17 H17 Br N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C15 H9 Br2 F N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H15 Cl N6 O4



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C22 H18 Cl2 N6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C17 H13 Cl2 F3 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

ALL ANSWERS HAVE BEEN SCANNED

10/759,749 2

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.90

1.11

STN INTERNATIONAL LOGOFF AT 08:25:05 ON 21 JAN 2007

10/759,749 3

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|--------------|--|--------|--|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | OCT 23 | The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded |
| NEWS | 4 | OCT 30 | CHEMLIST enhanced with new search and display field |
| NEWS | 5 | NOV 03 | JAPIO enhanced with IPC 8 features and functionality |
| NEWS | 6 | NOV 10 | CA/CAPLUS F-Term thesaurus enhanced |
| NEWS | 7 | NOV 10 | STN Express with Discover! free maintenance release Version 8.01c now available |
| NEWS | 8 | NOV 20 | CAS Registry Number crossover limit increased to 300,000 in additional databases |
| NEWS | 9 | NOV 20 | CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000 |
| NEWS | 10 | DEC 01 | CAS REGISTRY updated with new ambiguity codes |
| NEWS | 11 | DEC 11 | CAS REGISTRY chemical nomenclature enhanced |
| NEWS | 12 | DEC 14 | WPIDS/WPINDEX/WPIX manual codes updated |
| NEWS | 13 | DEC 14 | GBFULL and FRFULL enhanced with IPC 8 features and functionality |
| NEWS | 14 | DEC 18 | CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role |
| NEWS | 15 | DEC 18 | CA/CAPLUS patent kind codes updated |
| NEWS | 16 | DEC 18 | MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000 |
| NEWS | 17 | DEC 18 | MEDLINE updated in preparation for 2007 reload |
| NEWS | 18 | DEC 27 | CA/CAPLUS enhanced with more pre-1907 records |
| NEWS | 19 | JAN 08 | CHEMLIST enhanced with New Zealand Inventory of Chemicals |
| NEWS | 20 | JAN 16 | CA/CAPLUS Company Name Thesaurus enhanced and reloaded |
| NEWS | 21 | JAN 16 | IPC version 2007.01 thesaurus available on STN |
| NEWS | 22 | JAN 16 | WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data |
| | | | |
| NEWS EXPRESS | NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006. | | |
| | | | |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability | | |
| NEWS LOGIN | Welcome Banner and News Items | | |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 | | |
| NEWS X25 | X.25 communication option no longer available | | |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

10/759,749 3

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:39:48 ON 21 JAN 2007

=> file reg

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 0.21 | 0.21 |

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 08:39:55 ON 21 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JAN 2007 HIGHEST RN 917943-10-3

DICTIONARY FILE UPDATES: 19 JAN 2007 HIGHEST RN 917943-10-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\107597493.str



chain nodes :

7 15 16 17

ring nodes :

1 2 3 4 5 6 9 10 11 12 13 14

chain bonds :

4-7 5-17 7-9 13-15 14-16

ring bonds :

10/759,749 3

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
exact/norm bonds :
4-7 7-9 13-15
exact bonds :
5-17 14-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
isolated ring systems :
containing 1 : 9 :

G1

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 08:40:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 204 TO ITERATE

100.0% PROCESSED 204 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 3224 TO 4936

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

10/759,749 3

=> s l1 sss ful

FULL SEARCH INITIATED 08:40:30 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4123 TO ITERATE

100.0% PROCESSED 4123 ITERATIONS

11 ANSWERS

SEARCH TIME: 00.00.01

L3 11 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 08:40:37 ON 21 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jan 2007 VOL 146 ISS 5

FILE LAST UPDATED: 19 Jan 2007 (20070119/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 6 L3

=> d l4 1-6 bib hitstr

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:916886 CAPLUS

DN 145:314980

TI Preparation of aminopyridine compounds with spleen tyrosine kinase (Syk)-inhibitory activity

IN Kodama, Yoshitoshi; Noji, Satoru; Imamura, Katsuaki; Mizojiri, Ryo; Aoki, Kenta; Takagi, Hideo; Naka, Yuichi; Ito, Goro; Shinoda, Kiyotaka; Fujiwara, Akihito; Kurihara, Kazunori; Tanaka, Masaru

PA Japan Tobacco Inc., Japan

SO PCT Int. Appl., 467pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2006093247 | A1 | 20060908 | WO 2006-JP304034 | 20060224 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | US 2006205731 | A1 | 20060914 | US 2006-363563 | 20060228 |
| PRAI | JP 2005-52469 | A | 20050228 | | |
| | US 2005-658885P | P | 20050304 | | |
| | JP 2006-11751 | A | 20060119 | | |
| | US 2006-763045P | P | 20060127 | | |
| OS | MARPAT 145:314980 | | | | |
| IT | 909290-81-9P 909290-86-4P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of aminopyridine compds. as spleen tyrosine kinase (Syk) inhibitors for treatment and/or prevention of allergic diseases) | | | | |
| RN | 909290-81-9 CAPLUS | | | | |
| CN | Ethanone, 1-[5-[6-[[6-(dimethylamino)-4-pyrimidinyl]amino]-2-pyridinyl]-2-thienyl]- (9CI) (CA INDEX NAME) | | | | |




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 909290-86-4 CAPLUS

10/759,749 3

CN Ethanone, 1-[5-[6-[[6-(dimethylamino)-4-pyrimidinyl]amino]-2-pyridinyl]-2-thienyl]-, O-methyloxime (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1329661 CAPLUS

DN 144:69843

TI Preparation of pyrimidine derivatives and analogues as modulators of metabolism for the prophylaxis and treatment of metabolic-related disorders

IN Jones, Robert M.; Semple, Graeme; Xiong, Yifeng; Shin, Young-Jun; Ren, Albert S.; Lehmann, Juerg; Fioravanti, Beatriz; Bruce, Marc A.; Choi, Jin Sun Karoline

PA Arena Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 213 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2005121121 | A2 | 20051222 | WO 2005-US19318 | 20050602 |
| | WO 2005121121 | A3 | 20060316 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

PRAI US 2004-577354P P 20040604


IT 871679-03-7P, 6-[[[6-[[[1-(tert-Butoxycarbonyl)piperidin-4-yl]methyl](methyl)amino]pyrimidin-4-yl]amino]nicotinic acid
 871679-05-9P, 4-[[[6-[(5-Fluoropyridin-2-yl)amino]pyrimidin-4-yl](methyl)amino]methyl]piperidine-1-carboxylic acid tert-butyl ester
 871679-10-6P, 4-[[Methyl[6-[(5-trifluoromethylpyridin-2-yl)amino]pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylic acid tert-butyl ester

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine derivs. and analogs as modulators of metabolism for the prophylaxis and treatment of metabolic-related disorders)

RN 871679-03-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[[6-[[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]methyl]methylamino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 871679-05-9 CAPLUS

10/759,749 3


CN 1-Piperidinecarboxylic acid, 4-[[[6-[(5-fluoro-2-pyridinyl)amino]-4-pyrimidinyl]methylamino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 871679-10-6 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[methyl[6-[[5-(trifluoromethyl)-2-pyridinyl]amino]-4-pyrimidinyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:633921 CAPLUS
 DN 141:174079
 TI Preparation of 2-aminopyridines as cdk4 inhibitors
 IN Biwersi, Cathlin Marie; Mcnamara, Dennis Joseph; Repine, Joseph Thomas;
 Toogood, Peter Laurence; Vanderwel, Scott Norman; Warmus, Joseph Scott
 PA Warner-Lambert Company Llc, USA
 SO PCT Int. Appl., 89 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2004065378 | A1 | 20040805 | WO 2004-IB91 | 20040109 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ | | | | |
| | CA 2512646 | A1 | 20040805 | CA 2004-2512646 | 20040109 |
| | EP 1590341 | A1 | 20051102 | EP 2004-701058 | 20040109 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2004006809 | A | 20051227 | BR 2004-6809 | 20040109 |
| | JP 2006516561 | T | 20060706 | JP 2006-500296 | 20040109 |
| | US 2004236084 | A1 | 20041125 | US 2004-759749 | 20040116 |
| PRAI | US 2003-440805P | P | 20030117 | | |
| | WO 2004-IB91 | W | 20040109 | | |
| OS | MARPAT 141:174079 | | | | |
| IT | 733039-89-9P, N-Cyclopentyl-N'-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-4,6-diamine 733039-90-2P, N-Isopropyl-N'-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-4,6-diamine 733039-91-3P, 4-[6-[[6-(Cyclopentylamino)pyrimidin-4-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 733039-92-4P, N-[5-(3-Aminopyrrolidin-1-yl)pyridin-2-yl]-N'-cyclopentylpyrimidine-4,6-diamine | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (cdk4 inhibitor; preparation of 2-aminopyridines as cdk4 inhibitors for treating cell proliferative disorders) | | | | |
| RN | 733039-89-9 CAPLUS | | | | |
| CN | 4,6-Pyrimidinediamine, N-cyclopentyl-N'-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME) | | | | |



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-90-2 CAPLUS


CN 4,6-Pyrimidinediamine, N-(1-methylethyl)-N'-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-91-3 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[6-(cyclopentylamino)-4-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-92-4 CAPLUS

CN 4,6-Pyrimidinediamine, N-[5-(3-amino-1-pyrrolidinyl)-2-pyridinyl]-N'-cyclopentyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 3


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:107925 CAPLUS
DN 140:303243
TI Two-photon absorption properties of star-shaped compounds based on
1,3,5-triazine and 1,3,5-trisubstituted benzene
AU Zhou, Xin; Ren, Ai-Min; Feng, Ji-Kang; Liu, Xiao-Juan
CS Institute of Theoretical Chemistry, State Key Laboratory of Theoretical
and Computational Chemistry, Jilin University, Changchun, 130023, Peop.
Rep. China
SO THEOCHEM (2004), 668(2-3), 229-234
CODEN: THEODJ; ISSN: 0166-1280
PB Elsevier Science B.V.
DT Journal
LA English
IT 676520-46-0
RL: PRP (Properties)
(two-photon absorption properties of star-shaped compds. based on
1,3,5-triazine and 1,3,5-trisubstituted benzene)
RN 676520-46-0 CAPLUS
CN 2,4,6-Pyrimidinetriamine, N,N,N',N',N'',N''-hexa-2-pyridinyl- (9CI) (CA
INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 3


L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:43711 CAPLUS
DN 134:246534
TI S- and NH- bridging pyridine- and pyrimidine-based ligands for 2 +
2, 3 + 3 and 4 + 4 molecular grids: evidence of [2 +
2]Zn(II) grids
AU Tuntulani, Thawatchai; Tumcharern, Gamolwan; Volkmer, Dirk
CS Department of Chemistry, Faculty of Science, Chulalongkorn University,
Bangkok, 10330, Thailand
SO Bulletin of the Korean Chemical Society (2000), 21(12), 1245-1248
CODEN: BKCSDE; ISSN: 0253-2964
PB Korean Chemical Society
DT Journal
LA English
OS CASREACT 134:246534
IT 202583-29-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and complexation with zinc)
RN 202583-29-7 CAPLUS
CN 4,6-Pyrimidinediamine, N,N'-bis(4,6-dimethyl-2-pyridinyl)-2-methyl- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 3

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:104202 CAPLUS
DN 128:162178
TI Novel N-donor heterocyclic ligands and their coordination chemistry
towards a Cu(II) salt
AU Tuntulani, Thawatchai; Volkmer, Dirk; Fenske, Dieter; Lehn, Jean-Marie
CS Department of Chemistry, Faculty of Science, Chulalongkorn University,
Bangkok, 10330, Thailand.
SO Journal of the Science Society of Thailand (1997), 23(3), 185-198
CODEN: VKSTDB; ISSN: 0303-8122
PB Science Society of Thailand
DT Journal
LA English
IT 202583-29-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and complexation with copper)
RN 202583-29-7 CAPLUS
CN 4,6-Pyrimidinediamine, N,N'-bis(4,6-dimethyl-2-pyridinyl)-2-methyl- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 3

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

22.19

194.50

STN INTERNATIONAL LOGOFF AT 08:40:54 ON 21 JAN 2007